【摘要】：目的探討CXC亞族趨化因子受體3（CXCR3）及其配體I-TAC在免疫性血小板減少性紫癜（ITP）發(fā)病機(jī)制中的作用以及免疫抑制劑治療后的水平。 方法應(yīng)用酶聯(lián)免疫吸附試驗(yàn)（ELISA）和實(shí)時(shí)定量PCR（RT-PCR）法，對(duì)30例初診及復(fù)發(fā)ITP患者治療前、18例治療有效患者和24例健康人的血漿γ-干擾素（IFN-γ）、I-TAC的含量和外周血單個(gè)核細(xì)胞（PBMNC）CXCR3的相對(duì)表達(dá)進(jìn)行檢測(cè)。 結(jié)果（1）治療前ITP患者血漿中IFN-γ的含量（71.45±17.62）pg/ml明顯高于治療有效組（36.9±14.9）pg/ml與正常對(duì)照組（25.28±12.85）pg/ml（P0.05），ITP治療有效組血漿IFN-γ的含量仍高于正常對(duì)照組（P0.05）。（2）治療前ITP患者血漿中I-TAC的含量（455.56±144.70）pg/ml與治療有效組（488.24±164.70）pg/ml及正常對(duì)照組（382.97±167.43）pg/ml相比，三者之間無統(tǒng)計(jì)學(xué)意義（P0.05）。（3）與正常對(duì)照（相對(duì)表達(dá)中位數(shù)為0.12倍）（0.04，，0.28）相比，治療前（相對(duì)表達(dá)中位數(shù)為6.76倍）（3.03，37.00）與治療有效組（相對(duì)表達(dá)中位數(shù)為1.76倍）（0.45，14.18）ITP患者PBMNC高表達(dá)CXCR3mRNA（P0.05），治療有效后CXCR3表達(dá)降低，但與治療前組對(duì)比差異無統(tǒng)計(jì)學(xué)意義（P0.05）。 結(jié)論ITP患者表現(xiàn)Th1型細(xì)胞因子優(yōu)勢(shì)同時(shí)，CXCR3+細(xì)胞可能通過趨化機(jī)制在ITP免疫機(jī)制中發(fā)揮一定的作用。另外，免疫抑制治療對(duì)該作用軸有一定的影響。
[Abstract]:Objective to investigate the role of CXC subfamily chemokine receptor 3 (CXCR3) and its ligand I-TAC in the pathogenesis of immune thrombocytopenic purpura (ITP) and the level of immunosuppressive agents. Methods enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR (RT-PCR) were used to detect the content of plasma interferon-gamma (IFN- 緯), I-TAC and the relative expression of (PBMNC) CXCR3 in peripheral blood mononuclear cells in 30 patients with newly diagnosed and recurrent ITP, 18 patients with effective treatment and 24 healthy controls. Results (1) the content of IFN- 緯 in plasma of patients with ITP before treatment (41.45 鹵17.62) pg/ml was significantly higher than that of effective group (36.9 鹵14.9) pg/ml and normal control group (25.28 鹵12.85) pg/ml (P 0.05). The content of plasma IFN- 緯 in the effective group of ITP was still higher than that in the normal control group (P 0.05). (2). The content of I-TAC in the plasma of ITP patients before treatment was (455.56 鹵144.70) pg/ml, which was higher than that of the effective group (488.24 鹵164.70) pg/ml and the normal control group (382.97 鹵167.43) pg/ml. There was no significant difference among the three groups (P 0.05,). (3) compared with the normal control (the median relative expression was 0. 12 times) (0. 04, 0. 28). Before treatment (the median relative expression was 6. 76 times) (3.03, 37. 00) and the therapeutic effective group (1. 76 times) (0. 45,14. 18), the expression of CXCR3mRNA in PBMNC of ITP patients was lower than that of the control group (0. 45, 14. 18), and the expression of CXCR3 was decreased after treatment. However, there was no significant difference between the pre-treatment group and the pre-treatment group (P 0.05). Conclusion ITP patients show Th1 cytokine dominance, and CXCR3 cells may play a role in the immune mechanism of ITP through chemotactic mechanism. In addition, immunosuppressive therapy has a certain effect on the axis of action.
【學(xué)位授予單位】：青海大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類號(hào)】：R392

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 鄭紅;趨化因子及其受體的功能[J];免疫學(xué)雜志;2004年01期

2 姜培娟;林其德;鮑世民;趙愛民;肖世金;;趨化因子受體CCR3、CCR5和CXCR3與自然流產(chǎn)的相關(guān)性[J];上海交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2008年12期

3 王晨超;郭澍;唐明睿;肖汀;于學(xué)偉;張欣;吳劍;王凱波;;I-TAC和MDC在病理性瘢痕中的表達(dá)及意義[J];中國(guó)美容整形外科雜志;2008年05期

4 冀林華;任漢云;石永進(jìn);岑溪南;邱志祥;歐晉平;許蔚林;;血漿炎性趨化因子CXCL9/Mig水平與急性移植物抗宿主病關(guān)系的研究[J];中國(guó)實(shí)驗(yàn)血液學(xué)雜志;2006年06期

本文編號(hào)：2507669